NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1.	Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
Age and pregnancy were highlighted as protected characteristics. It was stated that inequalities may arise if different recommendations are made for children and pregnant women. All protected characteristics were considered by committee when making its recommendations. However, the committee can only make recommendations within a technology's marketing authorisation. The same recommendation is made for all people within the marketing authorisation.	

2.	Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
A stakeholder highlighted that danicopan is an oral therapy which means it would be easier for people with needle phobias and who have compromised venous access to comply with treatment. The committee noted that danicopan is given as an add-on to eculizumab (every 2 weeks) or ravulizumab (every 8 week), both of which are administered as intravenous infusions. So, it considered that venous access would still be required for danicopan add-on therapy. It was aware that the	

pegcetacoplan is usually given twice weekly via subcutaneous infusion and noted that this had been captured through an administration-related disutility in the model.

3.	Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No	

4.	Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

6.	Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A	

7.	Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

In section 3.16 of the draft guidance, it states that the committee did not identify any equality issues.

Approved by Associate Director (name): …Jasdeep Hayre

Date: 21 May 2024

Final draft guidance

(when draft guidance issued)

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
No	

2.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No	

3.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No	

4.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No	

5.	Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
In section 3.18 of the final draft guidance, it states that the committee did not identify any equality issues.	

Approved by Associate Director (name): Jasdeep Hayre

Date: 8 August 2024